Intrapulmonary pharmacokinetics of antibacterial agents: implications for therapeutics.
The idea of studying the pharmacokinetics and pharmacodynamics of antibacterials in order to predict their efficacy has long been of interest. Traditionally, serum drug concentrations have been evaluated against the minimum inhibitory concentration (MIC) of a given pathogen; however, infection site-specific data continue to gain interest from clinicians. Despite methodological limitations, progress in techniques has improved the clinical significance of data generated. Rather than using tissue homogenates which fail to differentiate between interstitial and intracellular concentrations, newer collection techniques focus on sampling of matrices that allow for this differentiation. These collection techniques now allow one to accurately describe beta-lactam and aminoglycoside interstitial penetrations, as well as, the interstitial and phagocytic concentrations of macrolides and fluoroquinolones. By using these specific data and the MICs of infecting pathogens, it is hoped that conclusions can be drawn by a clinician as to the appropriateness of the choice of an antibacterial.
Chiu
Loretta M
LM
The Clinical Pharmacology Research Center and Department of Adult and Pediatric Medicine, Bassett Healthcare, Cooperstown, New York 13326, USA.
Amsden
Guy W
GW
D000617:Aminoglycosides / Q000493:pharmacokinetics; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics*; D024841:Fluoroquinolones / Q000493:pharmacokinetics; D006020:Glycopeptides / Q000493:pharmacokinetics; D006801:Humans; D007769:Lactams / Q000493:pharmacokinetics; D018942:Macrolides / Q000493:pharmacokinetics; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000378:metabolism*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D006020:Glycopeptides; D007769:Lactams; D018942:Macrolides